Pharmacological treatments of neuropathic pain: The latest recommendations
We provide an up-to-date review of the pharmacological treatment of neuropathic pain with emphasis on the latest evidence-based recommendations for its pharmacological treatment. Drugs proposed as first line include tricyclic antidepressants (particularly amitriptyline), serotonin–norepinephrine reu...
Uloženo v:
| Vydáno v: | Revue neurologique Ročník 175; číslo 1-2; s. 46 - 50 |
|---|---|
| Hlavní autor: | |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
France
Elsevier Masson SAS
01.01.2019
Elsevier Masson |
| Témata: | |
| ISSN: | 0035-3787 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | We provide an up-to-date review of the pharmacological treatment of neuropathic pain with emphasis on the latest evidence-based recommendations for its pharmacological treatment. Drugs proposed as first line include tricyclic antidepressants (particularly amitriptyline), serotonin–norepinephrine reuptake inhibitors (particularly duloxetine), pregabalin and gabapentin. Second line treatments include lidocaine plasters and capsaicin high concentration patches for peripheral neuropathic pain only, and tramadol. Third line treatments include strong opioids and botulinum toxin A (for peripheral neuropathic pain). Perspectives include the development of new compounds and a more personalized therapeutic approach, which is made possible by recent progress in the assessment and understanding of neuropathic pain. |
|---|---|
| AbstractList | We provide an up-to-date review of the pharmacological treatment of neuropathic pain with emphasis on the latest evidence-based recommendations for its pharmacological treatment. Drugs proposed as first line include tricyclic antidepressants (particularly amitriptyline), serotonin-norepinephrine reuptake inhibitors (particularly duloxetine), pregabalin and gabapentin. Second line treatments include lidocaine plasters and capsaicin high concentration patches for peripheral neuropathic pain only, and tramadol. Third line treatments include strong opioids and botulinum toxin A (for peripheral neuropathic pain). Perspectives include the development of new compounds and a more personalized therapeutic approach, which is made possible by recent progress in the assessment and understanding of neuropathic pain.We provide an up-to-date review of the pharmacological treatment of neuropathic pain with emphasis on the latest evidence-based recommendations for its pharmacological treatment. Drugs proposed as first line include tricyclic antidepressants (particularly amitriptyline), serotonin-norepinephrine reuptake inhibitors (particularly duloxetine), pregabalin and gabapentin. Second line treatments include lidocaine plasters and capsaicin high concentration patches for peripheral neuropathic pain only, and tramadol. Third line treatments include strong opioids and botulinum toxin A (for peripheral neuropathic pain). Perspectives include the development of new compounds and a more personalized therapeutic approach, which is made possible by recent progress in the assessment and understanding of neuropathic pain. We provide an up-to-date review of the pharmacological treatment of neuropathic pain with emphasis on the latest evidence-based recommendations for its pharmacological treatment. Drugs proposed as first line include tricyclic antidepressants (particularly amitriptyline), serotonin–norepinephrine reuptake inhibitors (particularly duloxetine), pregabalin and gabapentin. Second line treatments include lidocaine plasters and capsaicin high concentration patches for peripheral neuropathic pain only, and tramadol. Third line treatments include strong opioids and botulinum toxin A (for peripheral neuropathic pain). Perspectives include the development of new compounds and a more personalized therapeutic approach, which is made possible by recent progress in the assessment and understanding of neuropathic pain. |
| Author | Attal, N. |
| Author_xml | – sequence: 1 givenname: N. surname: Attal fullname: Attal, N. email: nadine.attal@aphp.fr organization: Inserm U-987, centre d’évaluation et de traitement de la douleur, CHU Ambroise-Paré, AP–HP, 92100 Boulogne-Billancourt, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30318260$$D View this record in MEDLINE/PubMed https://hal.science/hal-03485634$$DView record in HAL |
| BookMark | eNqFkU1LxDAQhnNQ_P4HIj3qYdeZpt22HgQRdZUFPeg5pOnUzZI2a5IV_Pdm7erBg8JAIDzvQ_LOPtvqbU-MHSOMEXByvhj3tHLWjFPAcgxxIN9iewA8H_GiLHbZvvcLgBQL4DtslwPHMp3AHnt4mkvXSWWNfdVKmiQ4kqGjPvjEtsmXdinDXKtkKXV_kTzPKTEykA-JI2W7iDYyaNv7Q7bdSuPpaHMesJfbm-fr6Wj2eHd_fTUbqZxnYcSrSaWQl0gZ52lbV8RR5lnbEKR1QZgDzziVVDegSsIyn1SoUDUKsZI11vyAnQ3euTRi6XQn3YewUovp1Uys76Igpnj2jpE9Hdils2-r-GjRaa_IGNmTXXmRYgop8CKDiJ5s0FXdUfNj_u4qAhcDoJz13lErlA5fXw9OaiMQxHoZYiGGZYj1MgTEgTyGs1_hb_8_scshRrHQd01OeKWpV9To2H4QjdV_Cz4BlhSnFg |
| CitedBy_id | crossref_primary_10_1227_neu_0000000000002904 crossref_primary_10_3390_jcm11113002 crossref_primary_10_3390_molecules25235520 crossref_primary_10_1055_s_0043_1776135 crossref_primary_10_3389_fneur_2020_00778 crossref_primary_10_1097_MD_0000000000032417 crossref_primary_10_3390_pharmaceutics15071799 crossref_primary_10_1007_s12035_024_04511_y crossref_primary_10_1186_s13011_020_00292_4 crossref_primary_10_1097_j_pain_0000000000003413 crossref_primary_10_1080_21655979_2021_1976895 crossref_primary_10_3389_fnmol_2022_928587 crossref_primary_10_17116_jnevro202312304168 crossref_primary_10_1016_j_neuropharm_2022_109030 crossref_primary_10_1177_03000605211047704 crossref_primary_10_47373_rfcs_2024_v26_2324 crossref_primary_10_1007_s40267_019_00701_0 crossref_primary_10_3390_toxins15090541 crossref_primary_10_3390_toxins13090640 crossref_primary_10_1007_s11940_020_00652_2 crossref_primary_10_3390_ijms26073325 crossref_primary_10_3390_ph16081115 crossref_primary_10_1177_15291006211008157 crossref_primary_10_1016_j_fitote_2022_105224 crossref_primary_10_1080_14656566_2024_2374464 crossref_primary_10_1016_j_arr_2024_102249 crossref_primary_10_3390_ijms241511944 crossref_primary_10_3390_antiox11122361 crossref_primary_10_3389_fendo_2021_813210 crossref_primary_10_1038_s41598_022_11345_y crossref_primary_10_1016_j_gene_2024_148961 crossref_primary_10_1016_j_adaj_2020_08_017 crossref_primary_10_1111_bph_70183 crossref_primary_10_3390_biomedicines13071709 crossref_primary_10_3389_fnins_2023_1104862 crossref_primary_10_1007_s40261_022_01194_y crossref_primary_10_1097_GOX_0000000000003789 crossref_primary_10_2217_pmt_2021_0094 crossref_primary_10_1007_s40263_022_00914_4 crossref_primary_10_1111_papr_13175 crossref_primary_10_5114_ait_208941 crossref_primary_10_1111_papr_13176 crossref_primary_10_1111_ner_13222 crossref_primary_10_1016_j_neuropharm_2021_108909 crossref_primary_10_3390_jpm11080758 crossref_primary_10_1007_s00210_025_04134_7 crossref_primary_10_1134_S1819712423040219 crossref_primary_10_1007_s40265_020_01353_5 crossref_primary_10_1016_j_esmoop_2020_04_024 crossref_primary_10_3389_fnins_2025_1644961 crossref_primary_10_1111_ejn_15266 crossref_primary_10_52711_0974_360X_2022_00311 crossref_primary_10_36290_neu_2020_092 crossref_primary_10_1097_j_pain_0000000000002457 crossref_primary_10_3390_biology11111617 crossref_primary_10_1016_j_jpet_2025_103583 crossref_primary_10_2217_pmt_2023_0053 crossref_primary_10_1080_01616412_2021_2024719 crossref_primary_10_1111_papr_70029 crossref_primary_10_1080_10669817_2022_2092266 crossref_primary_10_1096_fj_202402381R crossref_primary_10_1017_S1092852922000128 crossref_primary_10_1080_14737175_2020_1794825 crossref_primary_10_1007_s00210_020_01995_y crossref_primary_10_1007_s40122_021_00261_0 crossref_primary_10_1016_j_taap_2021_115497 crossref_primary_10_3390_ph14090899 crossref_primary_10_1016_j_neurol_2021_07_004 crossref_primary_10_4274_tjps_galenos_2021_41514 crossref_primary_10_1002_ejp_1846 crossref_primary_10_1016_j_neuint_2024_105890 crossref_primary_10_1186_s13063_021_05088_w crossref_primary_10_1016_j_jep_2021_114737 crossref_primary_10_3390_gels9050417 crossref_primary_10_1096_fj_202101031RR crossref_primary_10_1007_s12325_020_01335_9 crossref_primary_10_1007_s00228_023_03612_2 crossref_primary_10_1055_a_1754_7150 crossref_primary_10_1016_j_jos_2021_08_016 crossref_primary_10_1007_s11055_023_01528_z crossref_primary_10_1007_s43440_024_00640_2 crossref_primary_10_1007_s00115_023_01563_8 crossref_primary_10_2174_0125899775321724240926114704 crossref_primary_10_1007_s13577_023_01019_w crossref_primary_10_1177_17448069251367596 crossref_primary_10_1186_s12891_023_06488_6 crossref_primary_10_1016_j_jtos_2024_04_004 crossref_primary_10_7759_cureus_79722 crossref_primary_10_1002_pmrj_12283 crossref_primary_10_3389_fnana_2024_1398400 crossref_primary_10_1097_SAP_0000000000002924 crossref_primary_10_1080_17512433_2023_2195626 crossref_primary_10_1016_j_jneuroim_2020_577457 crossref_primary_10_1007_s00482_023_00730_9 crossref_primary_10_4103_ijpn_ijpn_23_22 crossref_primary_10_3390_ijms24098359 crossref_primary_10_1002_2211_5463_13410 crossref_primary_10_1007_s00508_023_02167_7 crossref_primary_10_3390_jcm12041380 crossref_primary_10_3390_cells11244027 crossref_primary_10_1007_s40263_024_01072_5 crossref_primary_10_1016_j_pharmthera_2021_108032 crossref_primary_10_1016_j_neuropharm_2020_107949 crossref_primary_10_1016_j_lpm_2024_104232 crossref_primary_10_1186_s12974_022_02628_2 crossref_primary_10_3390_cimb47090719 crossref_primary_10_4155_ppa_2020_0007 crossref_primary_10_1002_ejp_2120 crossref_primary_10_1002_nop2_353 crossref_primary_10_3390_antiox11071321 crossref_primary_10_1007_s40265_023_01927_z crossref_primary_10_1213_ANE_0000000000006705 crossref_primary_10_1177_17448069211052167 crossref_primary_10_3389_fneur_2024_1424050 crossref_primary_10_1097_GOX_0000000000003570 crossref_primary_10_3390_antiox11030533 crossref_primary_10_1080_14737167_2022_2117691 crossref_primary_10_1111_eve_13199 crossref_primary_10_3390_toxins14100704 crossref_primary_10_1016_j_neurol_2019_01_398 crossref_primary_10_3390_jpm13111551 crossref_primary_10_1016_j_ejps_2024_106797 crossref_primary_10_1038_s41598_022_19109_4 crossref_primary_10_1097_j_pain_0000000000003063 crossref_primary_10_1097_JCP_0000000000001598 crossref_primary_10_12968_jowc_2024_0285 |
| Cites_doi | 10.1016/j.pain.2014.08.014 10.1155/2014/754693 10.1371/journal.pone.0150973 10.1523/JNEUROSCI.21-06-01868.2001 10.1111/j.1532-5415.2012.03923.x 10.1038/nrneurol.2013.180 10.1016/j.neuron.2012.02.008 10.1111/j.1468-1331.2010.02999.x 10.1136/bmj.c1079 10.1097/01.j.pain.0000460358.01998.15 10.1016/S0140-6736(09)61081-3 10.2165/00044011-200929060-00003 10.1016/S1474-4422(12)70189-8 10.1212/WNL.0000000000002840 10.1016/S1474-4422(14)70251-0 10.1002/ana.21542 10.1097/j.pain.0000000000000266 10.1097/j.pain.0000000000000602 10.1016/S0140-6736(13)62337-5 10.1111/dar.12089 10.1016/S1474-4422(13)70193-5 10.1016/j.ejpain.2011.03.005 10.1097/j.pain.0000000000000753 10.1016/S0304-3959(99)00007-X 10.1097/j.pain.0000000000000149 10.1016/j.pain.2013.05.043 10.1016/S1474-4422(16)00017-X 10.1038/nrdp.2017.2 10.1097/j.pain.0000000000001136 10.1016/j.neuroscience.2016.03.029 10.1111/j.1468-1331.2006.01511.x 10.1016/j.pain.2007.08.033 |
| ContentType | Journal Article |
| Copyright | 2018 Elsevier Masson SAS Copyright © 2018 Elsevier Masson SAS. All rights reserved. Attribution - NonCommercial |
| Copyright_xml | – notice: 2018 Elsevier Masson SAS – notice: Copyright © 2018 Elsevier Masson SAS. All rights reserved. – notice: Attribution - NonCommercial |
| DBID | AAYXX CITATION NPM 7X8 1XC VOOES |
| DOI | 10.1016/j.neurol.2018.08.005 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EndPage | 50 |
| ExternalDocumentID | oai:HAL:hal-03485634v1 30318260 10_1016_j_neurol_2018_08_005 S0035378718307276 |
| Genre | Journal Article Review |
| GroupedDBID | --- --M 08J 08T 0R~ 123 4.4 457 53G 5RE AACTN AADPK AAEDT AAEDW AAFWJ AAIAV AAKOC AALRI AAOAW AAXLA AAXUO ABFNM ABIVO ABLVK ABMAC ABMZM ABYKQ ACDAQ ACRLP ADBBV AEBSH AENEX AFKWA AFTJW AFXIZ AGUBO AIEXJ AIKHN AITUG AJBFU ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BNPGV CS3 DU5 EBS EFJIC EFLBG EJD F5P FDB FIRID FYGXN HZ~ KOM O9- P2P ROL SEM SES SPCBC SSH SSN SSZ T5K ZGI ZXP ~G- AAQFI AATTM AAXKI AAYWO AAYXX ABJNI ACIEU ACLOT ACVFH ADCNI AEIPS AEUPX AFJKZ AFPUW AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS NPM 7X8 1XC VOOES |
| ID | FETCH-LOGICAL-c534t-3969c1381e4332fb9e31a54fde02b7e150343e8ebd0c8e185691c1cdc119ab1b3 |
| ISICitedReferencesCount | 127 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000458414500007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0035-3787 |
| IngestDate | Tue Oct 14 20:46:30 EDT 2025 Sun Nov 09 11:21:57 EST 2025 Wed Feb 19 02:34:54 EST 2025 Tue Nov 18 22:08:58 EST 2025 Sat Nov 29 07:26:53 EST 2025 Fri Feb 23 02:17:57 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1-2 |
| Keywords | Recommendations Pharmacotherapy Personalized medicine Neuropathic pain |
| Language | English |
| License | Copyright © 2018 Elsevier Masson SAS. All rights reserved. Attribution - NonCommercial: http://creativecommons.org/licenses/by-nc |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c534t-3969c1381e4332fb9e31a54fde02b7e150343e8ebd0c8e185691c1cdc119ab1b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://hal.science/hal-03485634 |
| PMID | 30318260 |
| PQID | 2120203740 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | hal_primary_oai_HAL_hal_03485634v1 proquest_miscellaneous_2120203740 pubmed_primary_30318260 crossref_citationtrail_10_1016_j_neurol_2018_08_005 crossref_primary_10_1016_j_neurol_2018_08_005 elsevier_sciencedirect_doi_10_1016_j_neurol_2018_08_005 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-01-01 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – month: 01 year: 2019 text: 2019-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | France |
| PublicationPlace_xml | – name: France |
| PublicationTitle | Revue neurologique |
| PublicationTitleAlternate | Rev Neurol (Paris) |
| PublicationYear | 2019 |
| Publisher | Elsevier Masson SAS Elsevier Masson |
| Publisher_xml | – name: Elsevier Masson SAS – name: Elsevier Masson |
| References | Demant, Lund, Finnerup, Vollert, Maier, Segerdahl (bib0270) 2015; 156 Demant, Lund, Vollert, Maier, Segerdahl, Finnerup (bib0300) 2014 Cruccu, Finnerup, Jensen, Scholz, Sindou, Svensson (bib0220) 2016; 87 Finnerup, Attal, Haroutounian, McNicol, Baron, Dworkin (bib0215) 2015; 14 Bouhassira, Attal (bib0335) 2016; 338 Attal, Cruccu, Baron, Haanpää, Hansson, Jensen (bib0185) 2010; 17 Dworkin, O’Connor, Backonja (bib0195) 2007; 132 Attal, Bouhassira (bib0225) 2015; 156 Gilron, Bailey, Tu, Holden, Jackson, Houlden (bib0245) 2009; 374 Nolano, Simone, Wendelschafer-Crabb, Johnson, Hazen, Kennedy (bib0280) 1999; 81 American Geriatrics Society 2012 Beers Criteria Update Expert Panel (bib0235) 2012; 60 Santos, Alarcão, Fareleira, Vaz-Carneiro, Costa (bib0295) 2015; 2015 Bouhassira, Attal (bib0305) 2018; 159 Truini, Garcia-Larrea, Cruccu (bib0345) 2013; 9 Mankowski, Patel, Trueman, Bentley, Poole (bib0275) 2016; 11 Attal, Cruccu, Haanpaa, Hansson, Jensen, Nurmikko (bib0190) 2006; 13 Baron, Forster, Binder (bib0325) 2012; 11 Gilron, Jensen, Dickenson (bib0250) 2013; 12 NICE clinical guideline. Neuropathic pain- pharmacological management. http:/guidance nice org uk/CG173 Assessed June 24, 2014. Attal, Bouhassira, Baron, Dostrovsky, Dworkin, Finnerup (bib0320) 2011; 15 Binder, Bruxelle, Rogers, Hans, Bösl, Baron (bib0265) 2009; 29 Fischer, Jones, Urbanoski, Skinner, Rehm (bib0285) 2014; 33 Tesfaye, Wilhelm, Lledo, Schacht, Tölle, Bouhassira (bib0260) 2013; 154 Luo, Chaplan, Higuera, Sorkin, Stauderman, Williams (bib0240) 2001; 21 Edwards, Dworkin, Turk, Angst, Dionne, Freeman (bib0340) 2016; 157 Yalcin, Choucair-Jaafar, Benbouzid, Tessier, Muller, Hein (bib0230) 2009; 65 Emery, Luiz, Wood (bib0310) 2016 Baron, Maier, Attal, Binder, Bouhassira, Cruccu (bib0330) 2017; 158 Attal, de Andrade, Adam, Ranoux, Teixeira, Galhardoni (bib0290) 2016 Tan, Barry, Reken, Reken, Baker (bib0200) 2010; 340 Moulin, Boulanger, Clark, Clarke, Dao, Finley (bib0210) 2014; 19 Gilron, Tu, Holden, Jackson, DuMerton-Shore (bib0255) 2015; 156 Colloca, Ludman, Bouhassira, Baron, Dickenson, Yarnitsky (bib0180) 2017; 3 Rice, Dworkin, McCarthy, Anand, Bountra, McCloud (bib0315) 2014; 383 von Hehn, Baron, Woolf (bib0350) 2012; 73 Attal (10.1016/j.neurol.2018.08.005_bib0290) 2016 Colloca (10.1016/j.neurol.2018.08.005_bib0180) 2017; 3 Bouhassira (10.1016/j.neurol.2018.08.005_bib0335) 2016; 338 Attal (10.1016/j.neurol.2018.08.005_bib0320) 2011; 15 Finnerup (10.1016/j.neurol.2018.08.005_bib0215) 2015; 14 Fischer (10.1016/j.neurol.2018.08.005_bib0285) 2014; 33 Demant (10.1016/j.neurol.2018.08.005_bib0300) 2014 Gilron (10.1016/j.neurol.2018.08.005_bib0245) 2009; 374 Baron (10.1016/j.neurol.2018.08.005_bib0325) 2012; 11 American Geriatrics Society 2012 Beers Criteria Update Expert Panel (10.1016/j.neurol.2018.08.005_bib0235) 2012; 60 Santos (10.1016/j.neurol.2018.08.005_bib0295) 2015; 2015 Demant (10.1016/j.neurol.2018.08.005_bib0270) 2015; 156 Dworkin (10.1016/j.neurol.2018.08.005_bib0195) 2007; 132 Tesfaye (10.1016/j.neurol.2018.08.005_bib0260) 2013; 154 Baron (10.1016/j.neurol.2018.08.005_bib0330) 2017; 158 Rice (10.1016/j.neurol.2018.08.005_bib0315) 2014; 383 Attal (10.1016/j.neurol.2018.08.005_bib0185) 2010; 17 Edwards (10.1016/j.neurol.2018.08.005_bib0340) 2016; 157 von Hehn (10.1016/j.neurol.2018.08.005_bib0350) 2012; 73 Attal (10.1016/j.neurol.2018.08.005_bib0225) 2015; 156 Nolano (10.1016/j.neurol.2018.08.005_bib0280) 1999; 81 Gilron (10.1016/j.neurol.2018.08.005_bib0250) 2013; 12 Gilron (10.1016/j.neurol.2018.08.005_bib0255) 2015; 156 Binder (10.1016/j.neurol.2018.08.005_bib0265) 2009; 29 10.1016/j.neurol.2018.08.005_bib0205 Bouhassira (10.1016/j.neurol.2018.08.005_bib0305) 2018; 159 Moulin (10.1016/j.neurol.2018.08.005_bib0210) 2014; 19 Cruccu (10.1016/j.neurol.2018.08.005_bib0220) 2016; 87 Yalcin (10.1016/j.neurol.2018.08.005_bib0230) 2009; 65 Attal (10.1016/j.neurol.2018.08.005_bib0190) 2006; 13 Luo (10.1016/j.neurol.2018.08.005_bib0240) 2001; 21 Mankowski (10.1016/j.neurol.2018.08.005_bib0275) 2016; 11 Emery (10.1016/j.neurol.2018.08.005_bib0310) 2016 Tan (10.1016/j.neurol.2018.08.005_bib0200) 2010; 340 Truini (10.1016/j.neurol.2018.08.005_bib0345) 2013; 9 |
| References_xml | – volume: 12 start-page: 1084 year: 2013 ident: bib0250 article-title: Combination pharmacotherapy for management of chronic pain: from bench to bedside publication-title: Lancet Neurol – volume: 340 start-page: c1079 year: 2010 ident: bib0200 article-title: Guideline Development Group. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance publication-title: Br Med J – volume: 157 start-page: 1851 year: 2016 end-page: 1871 ident: bib0340 article-title: Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations publication-title: Pain – volume: 154 start-page: 2616 year: 2013 end-page: 2625 ident: bib0260 article-title: Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”–a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain publication-title: Pain – volume: 11 start-page: e0150973 year: 2016 ident: bib0275 article-title: Cost-Effectiveness of Capsaicin 8% Patch Compared with Pregabalin for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland publication-title: PLoS One – volume: 9 start-page: 572 year: 2013 end-page: 582 ident: bib0345 article-title: Reappraising neuropathic pain in humans--how symptoms help disclose mechanisms publication-title: Nat Rev Neurol – volume: 60 start-page: 616 year: 2012 end-page: 631 ident: bib0235 article-title: American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults publication-title: J Am Geriatr Soc – volume: 374 start-page: 1252 year: 2009 end-page: 1261 ident: bib0245 article-title: Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial publication-title: Lancet – volume: 156 start-page: 1440 year: 2015 end-page: 1448 ident: bib0255 article-title: Combination of morphine with nortriptyline for neuropathic pain publication-title: Pain – volume: 13 start-page: 1153 year: 2006 end-page: 1169 ident: bib0190 article-title: EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain publication-title: Eur J Neurol – volume: 383 start-page: 1637 year: 2014 end-page: 1647 ident: bib0315 article-title: EMA401-003 study group. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial publication-title: Lancet – volume: 81 start-page: 135 year: 1999 end-page: 145 ident: bib0280 article-title: Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation publication-title: Pain – volume: 159 start-page: 576 year: 2018 end-page: 582 ident: bib0305 article-title: Emerging therapies for neuropathic pain: new molecules or new indications for old treatments? publication-title: Pain – volume: 156 start-page: S104 year: 2015 end-page: S114 ident: bib0225 article-title: Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? publication-title: Pain – volume: 17 start-page: 1113 year: 2010 end-page: 1188 ident: bib0185 article-title: European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain. 2010 revision publication-title: Eur J Neurol – start-page: 1 year: 2016 end-page: 9 ident: bib0310 article-title: Na(v)1.7 and other voltage-gated sodium channels as drug targets for pain relief publication-title: Expert Opin Ther Targets – volume: 87 start-page: 220 year: 2016 end-page: 228 ident: bib0220 article-title: Trigeminal neuralgia: New classification and diagnostic grading for practice and research publication-title: Neurology – volume: 19 start-page: 328 year: 2014 end-page: 335 ident: bib0210 article-title: Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society publication-title: Pain Res Manag – year: 2014 ident: bib0300 article-title: The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study publication-title: Pain – volume: 15 start-page: 441 year: 2011 end-page: 443 ident: bib0320 article-title: Assessing symptom profiles in neuropathic pain clinical trials: Can it improve outcome? publication-title: Eur J Pain – volume: 14 start-page: 162 year: 2015 end-page: 173 ident: bib0215 article-title: Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and NeuPSIG recommendations publication-title: Lancet Neurol – year: 2016 ident: bib0290 article-title: Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial publication-title: Lancet Neurol – volume: 21 start-page: 1868 year: 2001 end-page: 1875 ident: bib0240 article-title: Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats publication-title: J Neurosci – volume: 65 start-page: 218 year: 2009 end-page: 225 ident: bib0230 article-title: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain publication-title: Ann Neurol – reference: NICE clinical guideline. Neuropathic pain- pharmacological management. http:/guidance nice org uk/CG173 Assessed June 24, 2014. – volume: 156 start-page: 2234 year: 2015 end-page: 2244 ident: bib0270 article-title: Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study publication-title: Pain – volume: 11 start-page: 999 year: 2012 end-page: 1005 ident: bib0325 article-title: Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach publication-title: Lancet Neurol – volume: 73 start-page: 638 year: 2012 end-page: 652 ident: bib0350 article-title: Deconstructing the neuropathic pain phenotype to reveal neural mechanisms publication-title: Neuron – volume: 132 start-page: 237 year: 2007 end-page: 251 ident: bib0195 article-title: Pharmacologic management of neuropathic pain: Evidence evidence-based recommendations publication-title: Pain – volume: 338 start-page: 27 year: 2016 end-page: 35 ident: bib0335 article-title: Translational neuropathic pain research: a clinical perspective publication-title: Neuroscience – volume: 3 start-page: 17002 year: 2017 ident: bib0180 article-title: Neuropathic pain publication-title: Nat Rev Dis Primers – volume: 158 start-page: 261 year: 2017 end-page: 272 ident: bib0330 article-title: Peripheral Neuropathic Pain: A mechanism-related organizing principle based on sensory profiles publication-title: Pain – volume: 2015 start-page: CD009923 year: 2015 ident: bib0295 article-title: Tapentadol for chronic musculoskeletal pain in adults publication-title: Cochrane Database Syst Rev – volume: 33 start-page: 19 year: 2014 end-page: 26 ident: bib0285 article-title: Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005-2011 publication-title: Drug Alcohol Rev – volume: 29 start-page: 393 year: 2009 end-page: 408 ident: bib0265 article-title: Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial publication-title: Clin Drug Investig – year: 2014 ident: 10.1016/j.neurol.2018.08.005_bib0300 article-title: The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study publication-title: Pain doi: 10.1016/j.pain.2014.08.014 – volume: 19 start-page: 328 year: 2014 ident: 10.1016/j.neurol.2018.08.005_bib0210 article-title: Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society publication-title: Pain Res Manag doi: 10.1155/2014/754693 – volume: 11 start-page: e0150973 issue: 3 year: 2016 ident: 10.1016/j.neurol.2018.08.005_bib0275 article-title: Cost-Effectiveness of Capsaicin 8% Patch Compared with Pregabalin for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland publication-title: PLoS One doi: 10.1371/journal.pone.0150973 – volume: 21 start-page: 1868 year: 2001 ident: 10.1016/j.neurol.2018.08.005_bib0240 article-title: Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats publication-title: J Neurosci doi: 10.1523/JNEUROSCI.21-06-01868.2001 – volume: 60 start-page: 616 year: 2012 ident: 10.1016/j.neurol.2018.08.005_bib0235 article-title: American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.2012.03923.x – volume: 9 start-page: 572 year: 2013 ident: 10.1016/j.neurol.2018.08.005_bib0345 article-title: Reappraising neuropathic pain in humans--how symptoms help disclose mechanisms publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2013.180 – volume: 73 start-page: 638 year: 2012 ident: 10.1016/j.neurol.2018.08.005_bib0350 article-title: Deconstructing the neuropathic pain phenotype to reveal neural mechanisms publication-title: Neuron doi: 10.1016/j.neuron.2012.02.008 – volume: 17 start-page: 1113 year: 2010 ident: 10.1016/j.neurol.2018.08.005_bib0185 article-title: European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain. 2010 revision publication-title: Eur J Neurol doi: 10.1111/j.1468-1331.2010.02999.x – volume: 340 start-page: c1079 year: 2010 ident: 10.1016/j.neurol.2018.08.005_bib0200 article-title: Guideline Development Group. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance publication-title: Br Med J doi: 10.1136/bmj.c1079 – volume: 156 start-page: S104 issue: Suppl 1 year: 2015 ident: 10.1016/j.neurol.2018.08.005_bib0225 article-title: Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? publication-title: Pain doi: 10.1097/01.j.pain.0000460358.01998.15 – start-page: 1 year: 2016 ident: 10.1016/j.neurol.2018.08.005_bib0310 article-title: Na(v)1.7 and other voltage-gated sodium channels as drug targets for pain relief publication-title: Expert Opin Ther Targets – volume: 374 start-page: 1252 year: 2009 ident: 10.1016/j.neurol.2018.08.005_bib0245 article-title: Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial publication-title: Lancet doi: 10.1016/S0140-6736(09)61081-3 – volume: 29 start-page: 393 year: 2009 ident: 10.1016/j.neurol.2018.08.005_bib0265 article-title: Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial publication-title: Clin Drug Investig doi: 10.2165/00044011-200929060-00003 – volume: 11 start-page: 999 year: 2012 ident: 10.1016/j.neurol.2018.08.005_bib0325 article-title: Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach publication-title: Lancet Neurol doi: 10.1016/S1474-4422(12)70189-8 – volume: 87 start-page: 220 year: 2016 ident: 10.1016/j.neurol.2018.08.005_bib0220 article-title: Trigeminal neuralgia: New classification and diagnostic grading for practice and research publication-title: Neurology doi: 10.1212/WNL.0000000000002840 – ident: 10.1016/j.neurol.2018.08.005_bib0205 – volume: 14 start-page: 162 year: 2015 ident: 10.1016/j.neurol.2018.08.005_bib0215 article-title: Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and NeuPSIG recommendations publication-title: Lancet Neurol doi: 10.1016/S1474-4422(14)70251-0 – volume: 65 start-page: 218 year: 2009 ident: 10.1016/j.neurol.2018.08.005_bib0230 article-title: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain publication-title: Ann Neurol doi: 10.1002/ana.21542 – volume: 156 start-page: 2234 year: 2015 ident: 10.1016/j.neurol.2018.08.005_bib0270 article-title: Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study publication-title: Pain doi: 10.1097/j.pain.0000000000000266 – volume: 157 start-page: 1851 year: 2016 ident: 10.1016/j.neurol.2018.08.005_bib0340 article-title: Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations publication-title: Pain doi: 10.1097/j.pain.0000000000000602 – volume: 383 start-page: 1637 year: 2014 ident: 10.1016/j.neurol.2018.08.005_bib0315 article-title: EMA401-003 study group. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial publication-title: Lancet doi: 10.1016/S0140-6736(13)62337-5 – volume: 33 start-page: 19 year: 2014 ident: 10.1016/j.neurol.2018.08.005_bib0285 article-title: Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005-2011 publication-title: Drug Alcohol Rev doi: 10.1111/dar.12089 – volume: 12 start-page: 1084 year: 2013 ident: 10.1016/j.neurol.2018.08.005_bib0250 article-title: Combination pharmacotherapy for management of chronic pain: from bench to bedside publication-title: Lancet Neurol doi: 10.1016/S1474-4422(13)70193-5 – volume: 15 start-page: 441 year: 2011 ident: 10.1016/j.neurol.2018.08.005_bib0320 article-title: Assessing symptom profiles in neuropathic pain clinical trials: Can it improve outcome? publication-title: Eur J Pain doi: 10.1016/j.ejpain.2011.03.005 – volume: 158 start-page: 261 year: 2017 ident: 10.1016/j.neurol.2018.08.005_bib0330 article-title: Peripheral Neuropathic Pain: A mechanism-related organizing principle based on sensory profiles publication-title: Pain doi: 10.1097/j.pain.0000000000000753 – volume: 81 start-page: 135 year: 1999 ident: 10.1016/j.neurol.2018.08.005_bib0280 article-title: Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation publication-title: Pain doi: 10.1016/S0304-3959(99)00007-X – volume: 156 start-page: 1440 issue: 8 year: 2015 ident: 10.1016/j.neurol.2018.08.005_bib0255 article-title: Combination of morphine with nortriptyline for neuropathic pain publication-title: Pain doi: 10.1097/j.pain.0000000000000149 – volume: 154 start-page: 2616 year: 2013 ident: 10.1016/j.neurol.2018.08.005_bib0260 article-title: Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”–a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain publication-title: Pain doi: 10.1016/j.pain.2013.05.043 – year: 2016 ident: 10.1016/j.neurol.2018.08.005_bib0290 article-title: Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(16)00017-X – volume: 2015 start-page: CD009923 issue: 5 year: 2015 ident: 10.1016/j.neurol.2018.08.005_bib0295 article-title: Tapentadol for chronic musculoskeletal pain in adults publication-title: Cochrane Database Syst Rev – volume: 3 start-page: 17002 year: 2017 ident: 10.1016/j.neurol.2018.08.005_bib0180 article-title: Neuropathic pain publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2017.2 – volume: 159 start-page: 576 year: 2018 ident: 10.1016/j.neurol.2018.08.005_bib0305 article-title: Emerging therapies for neuropathic pain: new molecules or new indications for old treatments? publication-title: Pain doi: 10.1097/j.pain.0000000000001136 – volume: 338 start-page: 27 year: 2016 ident: 10.1016/j.neurol.2018.08.005_bib0335 article-title: Translational neuropathic pain research: a clinical perspective publication-title: Neuroscience doi: 10.1016/j.neuroscience.2016.03.029 – volume: 13 start-page: 1153 year: 2006 ident: 10.1016/j.neurol.2018.08.005_bib0190 article-title: EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain publication-title: Eur J Neurol doi: 10.1111/j.1468-1331.2006.01511.x – volume: 132 start-page: 237 year: 2007 ident: 10.1016/j.neurol.2018.08.005_bib0195 article-title: Pharmacologic management of neuropathic pain: Evidence evidence-based recommendations publication-title: Pain doi: 10.1016/j.pain.2007.08.033 |
| SSID | ssj0021703 |
| Score | 2.5333207 |
| SecondaryResourceType | review_article |
| Snippet | We provide an up-to-date review of the pharmacological treatment of neuropathic pain with emphasis on the latest evidence-based recommendations for its... |
| SourceID | hal proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 46 |
| SubjectTerms | Life Sciences Neuropathic pain Personalized medicine Pharmacotherapy Recommendations |
| Title | Pharmacological treatments of neuropathic pain: The latest recommendations |
| URI | https://dx.doi.org/10.1016/j.neurol.2018.08.005 https://www.ncbi.nlm.nih.gov/pubmed/30318260 https://www.proquest.com/docview/2120203740 https://hal.science/hal-03485634 |
| Volume | 175 |
| WOSCitedRecordID | wos000458414500007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 issn: 0035-3787 databaseCode: AIEXJ dateStart: 20040601 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.sciencedirect.com omitProxy: false ssIdentifier: ssj0021703 providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3PT9swFLYGTNMu036v20DetBsKiusktnerJhBDDHFgUm9WYjsaiKUVTSv-_L0X22lVxIADl6iyYjfO5zw_P3_-HiHflOWFyOo0KUUqEvgS06TiuMvOBbcmt0Mpu4PCx-LkRI7H6jRks5916QRE08jrazV9VKihDMDGo7MPgLtvFArgN4AOV4AdrvcC_nQpRt0B0FPJPWkDxTi6NMRmd4pRgcC6uESfs93F9fFfuNmuBPKifLdbzJ2vj017srYfLG1bemb13moQAc8t9UGEYBh5DrYmzH3RMPqcJnEEhGOK3tCFuKGfMr107A1j7OMCF3v-yZBGJzu51DRfTj5xw31tTuqZgpGEdqF9Kxpb0Zg5E4Vrt4YiV2DLtkY_98dH_UKbiZRHOU7sVDwy2fH6bj7NbS7Jxh_kxt628OgckLOX5EVYOdCRR_wVeeKa1-TZr8CNeEOO1oCnS-DppKYrwFME_jsF2KmHna7B_pb8Ptg_-3GYhEwZicl51iZcFcowcL4cytHVlXKclXlWW5cOK-HA6ecZd9JVNjXSgYtWKGaYsYYxVVas4u_IZjNp3AdCZVHIQlljnBhmsmBSoQtsqqqSpra2GBAeX5Y2QUYes5lc6v9BNSBJX2vqZVTuuF9EHHRwBb2Lp2Fw3VHzK8DW_wmqpx-OjjWWwUuAnvNswQbkS0RVgznFPbKycZP5TIMnh3vzIksH5L2Hu2-L4wQI6_-PD-zMJ_J8-c19Jpvt1dxtk6dm0Z7PrnbIhhjLnTCE_wGtcKHY |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacological+treatments+of+neuropathic+pain%3A+The+latest+recommendations&rft.jtitle=Revue+neurologique&rft.au=Attal%2C+N.&rft.date=2019-01-01&rft.issn=0035-3787&rft.volume=175&rft.issue=1-2&rft.spage=46&rft.epage=50&rft_id=info:doi/10.1016%2Fj.neurol.2018.08.005&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_neurol_2018_08_005 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0035-3787&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0035-3787&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0035-3787&client=summon |